Study | Study design | Indication | Results-efficacy endpoint |
---|---|---|---|
Bosse & Kühner 1988[57] | randomized double-blind, multicenter study | Headache of different genesis | ASA + PARA + CAF* > 250 mg ASA + 250 mg PARA ASA + PARA + CAF* > 500 mg ASA |
Migliardi et al. 1994[48] | four identical, randomized double-blind, two-period crossover, multicenter studies | Tension-type headache | ASA + PARA + CAF** > 1000 mg PARA ASA + PARA + CAF** > Placebo |
Lipton et al. 1998[58] | three randomized, double-blind, studies. | Migraine | ASA + PARA + CAF** > Placebo |
Diener et al. 2005[59] | randomized double-blind, multicenter study | Migraine and tension-type headache | ASA + PARA + CAF*** > 500 mg ASA + 400 mg PARA ASA + PARA + CAF*** > 1000 mgASA ASA + PARA + CAF*** > 1000 mg PARA ASA + PARA + CAF*** > 100 mg CAF ASA + PARA + CAF*** > Placebo |
Goldstein et al. 2005[60] | randomized double-blind, multicenter study | Migraine | ASA + PARA + CAF** > 50 mg Sumatriptan ASA + PARA + CAF** > Placebo |
Goldstein et al. 2006[61] | randomized double-blind, multicenter study | Migraine | ASA + PARA + CAF** > 400 mg Ibuprofen ASA + PARA + CAF** > Placebo |